Clinical Trial Update: PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating a PD-1 antibody with chemoradiotherapy for recurrent nasopharyngeal carcinoma. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• PD-1 antibody (PD-1 inhibitor)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Recurrent Nasopharyngeal Carcinoma | Phase 3 | Status: RECRUITING